¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"high dose tolerance"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • high frequency current
    °íÁÖÆÄÀü·ù
  • high frequency filter
    °íÁÖÆÄ¿©°ú±â, °íÁ֯İŏ£°³
  • high frequency recombination
    °íºóµµÀçÁ¶ÇÕ
  • high frequency transducing lysate
    °íºóµµÇüÁúµµÀÔ¿ëÇØ¹°
  • high frequency transduction
    °íºóµµÇüÁúµµÀÔ
  • high insertion
    °íÀ§ºÎÂø
  • high intensity proton flow
    °í°­µµ¾çÀÚÈ帧, °í°­µµ¾çÀÚÀ¯µ¿
  • high pelvic position
    ³ôÀº°ñ¹ÝÀÚ¼¼
  • high polymer chemistry
    °íºÐÀÚÈ­ÇÐ
  • high potency
    1. °íÈ¿´É, °í¿ª°¡ 2. °íÀáÀç·Â
  • high power application
    °íÃâ·ÂÀû¿ë
  • high residue diet
    °íÀÜ·ùÀ½½Ä
  • high resolution
    °íÇØ»óµµ
  • high resolution computed tomography
    °íÇØ»óÄÄÇ»ÅÍ´ÜÃþÃÔ¿µ(¼ú)
  • high risk group
    °íÀ§Ç豺
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • self tolerance
    ÀÚ±â¸é¿ªÇã¿ë
  • sitting tolerance
    ÁÂÀ§³»¼º, ¾ÉÀ½³»¼º
  • split tolerance
    ºÐÇҸ鿪Çã¿ë
  • tolerance
    ³»¼º, °ßµõ, Çã¿ë, °ü¿ë
  • thermal tolerance
    ¿­³»¼º
  • toxic tolerance
    µ¶¹°³»¼º
  • high power application
    °íÃâ·ÂÀû¿ë
  • high spatial frequency algorithm
    °í°ø°£Á֯ļö¿¬»ê
  • high energy bond
    °í¿¡³ÊÁö°áÇÕ
  • high speed core cut biopsy
    °í¼ÓÁ߽ɻý°Ë
  • high frequency current
    °íÁÖÆÄÀü·ù
  • high polymer chemistry
    °íºÐÀÚÈ­ÇÐ
  • high-performance liquid chromatography
    °íÀÛÀ§¾×üũ·Î¸¶Åä±×·¡ÇÇ
  • high-pressure liquid chromatography
    °í¾Ð·Â¾×üũ·Î¸¶Åä±×·¡ÇÇ
  • high-threshold cell
    °í¹®Åΰª¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • insulin tolerance
    Àν¶¸°³»¼º.
  • insulin tolerance test
    Àν¶¸°³»¼º½ÃÇè.
  • insulin tolerance test
    Àν¶¸°³»¼º½ÃÇè
  • pharmacodynamic tolerance
    ¾à¿ªÇÐÀû ³»¼º.
  • poison tolerance
    µ¶¹°³»¼º(Ô¸ÚªÒ±àõ).
  • radiation tolerance
    ¹æ»ç¼± °ßµõ
  • ED 50=£¾effective dose 50%
    50% À¯È¿·®, Áß°£À¯È¿·®.
  • ED 50=£¾effective dose 50%
    50% À¯È¿·®.
  • ED 50=ÊÝeffective dose 50%
    50% À¯È¿·®.
  • ED=ÊÝeffective dose
    À¯È¿·®.
  • ID50 (50% infectious dose)
    50% °¨¿°·®
  • LD = lethal dose
    Ä¡»ç·®.
  • LD50 (50% lethal dose)
    50% Ä¡»ç·®
  • LD= lethal dose
    Ä¡»ç·®.
  • MED => minimum effective dose
    ÃÖ¼ÒÈ«¹Ý·®
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • carbohydrate tolerance test
    ź¼öÈ­¹°ºÎÇϽÃÇè.
  • cortisone glucose tolerance test =CGTT
    ÄÚ¸£Æ¼¼Õ Æ÷µµ´ç ºÎÇϽÃÇè(¡­øã Ô¬ÓØÝ¶ùÃãËúÐ).
  • cross tolerance
    ±³Â÷³»¼º(Îßó©Ò±àõ)
  • cross tolerance
    ±³Â÷¸é¿ª°ü¿ë
  • cross-tolerance
    ±³Â÷³»¼º(Îßó©Ò±àõ)
  • diabetes mellitus,oral glucose tolerance test
    °æ±¸´çºÎÇÏ °Ë»ç(ÌèÏ¢ÓØÝ¶ùà ËþÞÛ)
  • drug disposition tolerance
    ¾à¹°ºÐÇØ³»¼º.
  • drug tolerance
    ¾à¹°<¾àÁ¦>³»¼º.
  • drug tolerance
    ¾à¹°³»¼º(å·ÚªÒ±àõ).
  • exercise tolerance
    ¿îµ¿Çã¿ë´É(ê¡ÔÑúÉé»Òö).
  • exercise tolerance
    ¿îµ¿Çã¿ë´É.
  • exercise tolerance
    ¿îµ¿Çã¿ë´É
  • exercise tolerance test
    ¿îµ¿ºÎÇϰ˻ç(ê¡ÔÑݶùÃËþÞÛ).
  • exercise tolerance test
    ¿îµ¿ºÎÇϰ˻ç.
  • exercise tolerance test
    ¿îµ¿ºÎÇϰ˻ç
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • high-temperature protection regulon
    °í¿Âº¸È£(ÍÔè®ÜÁûÞ) ·¹±Ö·Ð
  • high-temperature-short-time method
    °í¿Â ´Ü½Ã°£¹ý(ÍÔè®Ó­ãÁÊàÛö)
  • high-voltage electrophoresis
    °íÀü¾Ð Àü±â¿µµ¿(ÍÔï³äâï³Ñ¨ç¶ÔÑ)
  • very high-density lipoprotein
    Ãʰí¹Ðµµ(õ±ÍÔÚËÓø) ÁöÁú´Ü¹éÁú(ò·òõÓ±ÛÜòõ)
  • very high-lipid lipoprotein
    ÃʰíÁöÁú(õ±ÍÔò·òõ) ÁöÁú´Ü¹éÁú(ò·òõÓ±ÛÜòõ)
  • absorbed dose
    Èí¼ö·® (ýåâ¥Õá)
  • air dose
    ´ë±â¼±·®(ÓÞѨàÊÕá)
  • booster dose
    ºÎ½ºÅÍ ·®(Õá)
  • dose-response curve
    ¿ë·®´ëÀÀ °î¼±(é»ÕáÓßëëÍØàÊ)
  • exposure dose
    ³ëÃâ·®(ÖÚõóÕá)
  • fractionated dose
    ºÐÇÒ·®(ÝÂùÜÕá)
  • half-value dose
    ¹Ý(Úâ)°ª ¼±·®(àÊÕá)
  • lethal dose
    Ä¡»ç·®(öÈÞÝÕá)
  • maximum permissible dose
    ÃÖ´ëÇã¿ë·®(õÌÓÞúÉé»Õá)
  • median effective dose
    Á¤Áß À¯È¿·®(ïáñéêóüùÕá)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • high output heart failure
    °í¹ÚÃ⼺½ÉºÎÀü
  • high power application
    °íÃâ·ÂÀû¿ë
  • high protein diet
    °í´Ü¹é½ÄÀÌ
  • high quality scanning
    °íÁúÀÇ ½ºÄ³´×
  • high resolution
    °íÇØ»ó(µµ)
  • high resolution computed tomography [=HRCT]
    °íÇØ»óÀü»êÈ­´ÜÃþÃÔ¿µ¼ú
  • high risk group
    °íÀ§Çèµµ±º
  • high signal
    °í½ÅÈ£
  • high signal intensity
    °í½ÅÈ£°­µµ
  • high spatial frequency algorithm
    °í°ø°£Á֯ļö¿¬»ê
  • high speed
    °í¼ÓÀÇ
  • high speed core cut biopsy
    °í¼ÓÁ߽ɻý°Ë
  • high velocity signal loss
    °í¼Óµµ½ÅÈ£¼Ò½Ç
  • high voltage radiography
    °í¾ÐÃÔ¿µ¼ú
  • high voltage radiography
    °íÀü¾ÐÃÔ¿µ¼ú
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
LD labor and delivery; laboratory data; labyrinthine defect; lactate dehydrogenase; laser Doppler; lear...
MD Doctor of Medicine [Lat. Medicinae Doctor]; magnesium deficiency; main duct; maintenance dose; major...
MID maximum inhibiting dilution; mesioincisodistal; midinfarct dementia; minimum infective dose; minimum...
NSD Nairobi sheep disease; neonatal staphylococcal disease; neurosecretory dysfunction; night sleep depr...
TCD tapetochoroidal dystrophy; T-cell depletion; thermal conductivity detector; tissue culture dose; tra...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
HDM High-dose melphalan
ETT Exercise Tolerance Test
FTQ Fagerstrom Tolerance Questionnaire
FSIGTT Frequently sampled intravenous glucose tolerance test
GTF Glucose Tolerance Factor
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • high fever
    °í¿­
    ³ôÀº ¿­.
  • high frequency
    °íºóµµ, °íÁÖÆÄ
    ¿¡³ÊÁö°¡ ÀÚÁÖ ¹ß»ýµÇ´Â °Í. ºóµµ°¡ ³ôÀº °Í.
  • high frequency heating
    °íÁÖÆÄ °¡¿­
  • high frequency wave
    °íÁÖÆÄ
  • high intensity proton flow
    °í°­µµ ¾çÀÚÀ¯µ¿
  • high lip line
    »ó¼ø¼±
    À­ ÀÔ¼úÀÇ À§ÂÊ °æ°è.
  • high pain threshold
    °í µ¿Åë ¿ªÄ¡
    ÅëÁõÀ» À¯¹ßÇØ ¹ÝÀÀÀ» ÀÏÀ¸Å°°Ô ÇÏ´Â ÃÖ¼ÒÇÑÀÇ ÀÚ±ØÀÇ °­µµ°¡ ³ôÀº °Í.
  • high power application
    °íÃâ·Â Àû¿ë
  • high protein diet
    °í´Ü¹é ½ÄÀÌ
  • high pull headgear
    »ó¹æ °ßÀÎÇü Çìµå ±â¾î
  • high repitition rate
    °í¹Ýº¹À², ³ôÀº ¹Ýº¹À²
  • high resolution banding technique
    °íÁ¤µµ ¿°»öü ºÐ¿°¹ý
  • high risk group
    °íÀ§Çèµµ±º
  • high signal intensity
    °í½ÅÈ£ °­µµ
  • high speed core cut biopsy
    °í¼Ó Á᫐ »ý°Ë
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
air dose The radiation dose, expressed in roentgens, delivered at a point in free air.
Synonym: air dose.
(05 Mar 2000)
bone marrow dose The cumulative dose to the blood-forming organ from therapeutic or nuclear fallout irradiation; the presumed leukemogenic dose.
(05 Mar 2000)
booster dose A dose given at some time after an initial dose to enhance the effect, said usually of antigens for the production of antibodies.
(05 Mar 2000)
breast dose in mammography <radiology> 180 mrad / view -- mid-breast dose, guideline: less than 1 rad for 2-view exam
(12 Dec 1998)
maintenance dose In chemotherapy, systematic dosage at a level that maintains protection against exacerbation.
(05 Mar 2000)
genetically significant dose <physics, radiobiology> The genetically significant dose is that which, if received by every member of the population, would be expected to produce the same genetic injury to the population as do the actual doses received by the individuals irradiated.
Thus, the genetically significant dose is the dose equivalent to the gonads weighted for the age and sex distribution in those members of the irradiated population expected to have offspring. The genetically significant dose is expressed in sieverts (or rem).
Acronym: GSD
(06 Aug 1998)
maximal dose <pharmacology> The largest amount of a drug or physical procedure that an adult can take with safety.
(05 Mar 2000)
maximum permissible dose <radiobiology> Defined by the International Commission on Radiological Protection as the greatest dose of radiation which, in the light of present knowledge, is not expected to cause detectable bodily injury to a person at any time during his lifetime.
This dose has been reduced with each Commission report. The MPD is given in terms of acute or chronic exposure of the whole body or of organs, systems, or regions of the body, and differs for persons who are occupationally exposed versus the public at large.
(05 Mar 2000)
median effective dose The dose that produces the desired effect; when followed by a subscript (generally "ED50"), it denotes the dose having such an effect on a certain percentage (e.g., 50%) of the test animals; ED50 is the median effective dose, in radiation protection, the sum of the equivalent doses in all tissues and organs of the body weighted for tissue effects of radiation. The unit of effective dose is the sievert (Sv), epilation dose, the minimum amount of radiation sufficient to produce hair loss, usually in 10 to 14 days.
(05 Mar 2000)
gonadal dose The exposure dose to the male or female gonad, usually from incidental secondary radiation in diagnostic or therapeutic irradiation, or from whole-body irradiation.
Synonym: gonadal dose.
(05 Mar 2000)
gonad dose The exposure dose to the male or female gonad, usually from incidental secondary radiation in diagnostic or therapeutic irradiation, or from whole-body irradiation.
Synonym: gonadal dose.
(05 Mar 2000)
minimal dose <pharmacology> The smallest amount of a drug or physical procedure that will produce a desired physiologic effect in an adult.
(05 Mar 2000)
minimal infecting dose <microbiology> The smallest quantity of infectious material regularly producing infection; usually expressed as I.D.50, the quantity causing infection in 50% of a suitable series of animals or cells (cell cultures).
(05 Mar 2000)
minimal lethal dose <pharmacology> The minimal dose of a toxic substance or infectious agent that is lethal, as assayed in various experimental animals (e.g., the least amount of diphtheria toxin that, on an average, kills a 250-g guinea pig within 96 hours after subcutaneous inoculation).
When followed by a subscript (generally "MLD50"), denotes the minimal dose that is lethal to a certain percentage (e.g., 50%) of animals so assayed, LD05.
See: lethal dose.
(05 Mar 2000)
minimal reacting dose The minimal dose of a toxic substance causing a reaction, as manifested in the skin of a series of susceptible test animals; the assay is based on the development of a characteristic, minimal but definite, "standard," focal inflammation (congestion and oedema, induration, degenerative changes, and desquamation of epidermal cells).
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • high Strung
    Å«°Å¸®;Á߽ɰ¡
  • high altar
    (±³È¸´çÀÇ)ÁÖ Á¦´Ü;Áß¾Ó Á¦´Ü
  • high analysis
    (ºñ·á°¡)½Ä¹°ÀÇ ÇÊ¿ä ¾çºÐÀÇ 20% ÀÌ»óÀ» ÇÔÀ¯ÇÏ´Â
  • high atmospheric pressure
    °í±â¾Ð
  • high beam
    ÇÏÀ̺ö(¿ø°Å¸®¿ë »óÇâ Çìµå¶óÀÌÆ®)
  • high blood pressure
    °íÇ÷¾Ð
  • high blower
    Äà±èÀ» ¼¼°Ô ³»½¬´Â ¸»
  • high boot
    ÀåÈ­
  • high brass
    =top brass
  • high camp
    ¿¹¼úÀûÀ¸·Î ÁøºÎÇÑ °ÍÀ» ÀǵµÀûÀ¸·Î ÀÌ¿ëÇϱâ
  • high chair
    (¾î¸°ÀÌÀÇ)½Ä»ç¿ë ³ôÀº ÀÇÀÚ
  • high color
    ÁÁÀº Ç÷»ö
  • high comedy
    (¿¬±âÀÇ ÀÍ»ì µûÀ§¿¡ ÁßÁ¡À» µÎÁö ¾Ê´Â)°í±ÞÈñ±Ø
  • high command
    ÃÖ°í »ç·ÉºÎ
  • high commissioner
    (½Ä¹ÎÁöÀÇ)°íµî ÆÇ¹«°ü !
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á